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Introduction: Immunotherapy with the anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody ipilimumab
has been shown to improve overall survival in previously treated and treatment-naïve patients with unresectable
stage III or IV melanoma. Consistent with its proposed immunomodulating mechanism of action, the most common
toxicities associated with ipilimumab therapy are immune-related in nature and include those related to the skin
and gastrointestinal tract, with endocrine and hepatic events also frequent. Other rare adverse events, including
haematological aberrations, may also occur and can have serious consequences if unrecognised. Here we describe
three patients who developed serious haematological adverse events during or after treatment with ipilimumab.
Case presentation: Three Caucasian patients (two women aged 68 and 49 years and one man aged 70 years) with
metastatic melanoma experienced anaemia and/or leukopenia (neutropenia) with toxicity of various grades during
or after treatment with ipilimumab, without significant changes to other haematological values. Two of the patients
stopped treatment after the third ipilimumab dose, one because of severe anaemia that required blood transfusion
and the other due to febrile neutropenia that was treated with antibiotics and granulocyte-macrophage
colony-stimulating factor stimulation. The third patient developed anaemia and leukopenia after treatment during
the follow-up period. The results of autoimmunity tests performed were positive and corticosteroids were used
to treat these events as per side-effects treatment algorithms specifically developed for the management of
immune-related adverse events associated with ipilimumab, an approach that was safe and effective.
Conclusions: Haematological toxicity is a rare but potentially serious immune-related side effect of ipilimumab
therapy. However, if promptly recognised and treated, haematological toxicity is manageable and can be reversed
with standard corticosteroid treatment as recommended for other ipilimumab immune-related side effects.
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ToxicityIntroduction
Immunotherapy with the anti-cytotoxic T-lymphocyte anti-
gen-4 (anti-CTLA-4) monoclonal antibody ipilimumab has
been shown to improve overall survival in previously
treated and treatment-naïve patients with unresectable
stage III or IV melanoma [1,2]. As a result of these find-
ings, ipilimumab has become a new standard of therapy
for metastatic melanoma, being approved as first- and
second-line treatment in Europe, the USA and elsewhere.* Correspondence: paolo.ascierto@gmail.com
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unless otherwise stated.However, because CTLA-4 plays a key role in regulating
tolerance to self-antigens, ipilimumab can result in auto-
immune damage of various organ systems, leading to
sometimes life-threatening or fatal immune-related adverse
events. Increasing use of ipilimumab in clinical practice
has resulted in improved knowledge of its safety profile
with the most frequent toxicities now well known, in par-
ticular cutaneous, gastrointestinal, endocrine and hepatic
side effects [3]. Other less common adverse effects can also
occur. For instance, a recent review of ipilimumab-related
adverse events in 702 patients included previously unre-
ported toxicities such as drug rash with eosinophilia and
systemic symptoms, ischemic gastritis, granulomatous in-
flammation of the central nervous system, and aseptical Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Simeone et al. Journal of Medical Case Reports 2014, 8:240 Page 2 of 5
http://www.jmedicalcasereports.com/content/8/1/240meningitis [4]. In addition, although uncommon, haemato-
logical toxicities have also been previously documented,
with reports in the literature of anaemia and neutropenia
associated with ipilimumab therapy [5-7]. If unrecognised
and not promptly treated, these side effects can have ser-
ious consequences. Here we describe three patients who
participated in the Italian Expanded Access Programme
(EAP) [8] and who developed serious haematological




A 68-year-old Caucasian woman presented with meta-
static disease of an unknown primary melanoma, with dis-
ease characterised by in-transit lesions that were treated
with repeated surgery. Six years later disease progression
comprising a bilateral renal mass was diagnosed, at which
time she started chemotherapy with temozolomide. After
progression 1 month later, she was started on ipilimumab
3mg/kg. There were no significant side effects for the first
three ipilimumab doses. However, before the fourth dose,
she experienced symptoms of fatigue and mild dyspnoea.
A blood test showed an acute decrease in her haemo-
globin (Hb) level, with a value of 6.0g/dL. She was
discontinued from the EAP and hospitalised. Cross-
testing for blood transfusion showed positivity; anaemia of
autoimmune origin was suspected. This diagnosis was
confirmed through laboratory evaluation involving: hae-
matology tests (haematocrit 16%; white blood cell (WBC),
9200/μL; platelets 235,000/μL) with reticulocyte evalu-
ation (elevated, 0.2% with absolute count 1.9K/μL); assess-
ment of serum iron (normal, 215μg/mL), serum ferritin
(high, 900ng/mL), total bilirubin (elevated, 2.5mg/dL, with
indirect fraction also high, 1.5mg/dL), and lactate de-
hydrogenase (elevated, 580U/L); peripheral blood smear
(spherocytes and normal WBCs and platelets); and a posi-
tive direct Coombs test. A bone marrow biopsy was not
considered necessary in this case, given that her WBC and
platelet counts were normal and so not suggestive of bone
marrow invasion and because other diagnostic tests were
sufficient to indicate haemolytic autoimmune anaemia.
Due to this diagnosis, she was started on high-dose meth-
ylprednisolone (125mg twice a day) before a selective
blood transfusion was performed with washed red cells.
Her Hb level increased by 2g/dL in the first 24 hours and
then progressively over the course of a week. High-dose
corticosteroids were continued until her Hb level in-
creased and was maintained at the higher level for 1 week;
corticosteroids were then tapered over a 4-week period.
She was monitored with a haematology test once a week
for the first month. Her Hb returned to normal ranges
without showing any other alterations. Tumour assess-
ment by a computed tomography (CT) scan showed stabledisease that has been maintained until the present time
(December 2013).
Case report 2
A 49-year-old Caucasian woman presented with a diagno-
sis of stage IIIC melanoma of the trunk. The first evidence
of disease progression was detected 7 months later with
metastases to her bone and brain. A bone marrow biopsy
showed lymphocyte infiltration without evidence of other
malignant cells. Chemotherapy with fotemustine for two
cycles was initiated, but she developed progressive meta-
static disease to her brain. After a further 2 months, she
underwent CyberKnife® radiosurgery, after which she
started ipilimumab at 3mg/kg. After the third dose of ipili-
mumab, she developed severe leukopenia and neutropenia
(WBC count 1×103/μL, neutrophils 1%) with fever (39°C).
Blood tests showed no infection and other haematological
values were normal. She was promptly hospitalised and
treated with antibiotics, granulocyte-macrophage colony-
stimulating factor (GM-CSF) and high doses of intra-
venous methylprednisolone (2mg/kg twice a day) until
improvement and resolution after 10 days. Her methyl-
prednisolone dose was tapered over 8 weeks. Subsequent
brain magnetic resonance imaging and whole-body CT
scans showed a partial response in her brain and bone.
She maintained this partial response with normal blood
tests for 13 months, after which rapid brain disease pro-
gression occurred and she died.
Case report 3
The third patient was a 70-year-old Caucasian man who
received a diagnosis of ocular melanoma, with the first
recurrence to laterocervical lymph nodes being excised
after 2 years. After a further 2-year period, he developed
bilateral lung metastases and started chemotherapy with
fotemustine for three cycles, with stable disease for 2
years. Progressive disease metastatic to his lungs was
then diagnosed and he received ipilimumab 3mg/kg for
four cycles, with stable disease after 12 weeks. The only
side effect of ipilimumab was mild pruritus that resolved
itself after treatment was complete. At week 48 (from ini-
tiation of ipilimumab), assessment of his tumour showed
a complete response. During follow-up, he developed se-
vere anaemia (Hb 7.0g/dL) and leukopenia (WBC 900/μL,
neutrophils 32%) without fever. Tumour restaging still
showed a complete response. A bone marrow biopsy was
performed and showed lymphocyte infiltration without
evidence of other malignancies or melanoma cells while a
peripheral blood smear showed an absence of blasts or
fibrosis and normal cellularity. His WBCs and red blood
cells (RBCs) were normal even though CD4 and CD8 lym-
phocytes were increased in both bone marrow and periph-
eral blood. No cytogenic alterations were found and no
haemolysis was observed. He was successfully treated with
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effects treatment algorithm) and GM-CSF for 1 week. His
haematological test results returned to normal and pred-
nisone was tapered over 4 weeks. To date, he maintains a
complete response with no other haematological alterations.
Discussion
Haematological toxicity may potentially involve all blood
cell types due to autoimmunity, but the three patients de-
scribed here have anaemia and/or leukopenia (neutropenia)
with toxicity of various grades without significant changes
to other haematological values. Two of the patients stopped
treatment after the third ipilimumab dose, one because of
severe anaemia that required blood transfusion and the
other due to febrile neutropenia that was treated with anti-
biotics and GM-CSF stimulation. The third patient devel-
oped anaemia and leukopenia during the follow-up period.
In patients who develop haematological toxicity during
treatment, the first steps are to exclude other causes
through bone marrow biopsy to assess metastatic involve-
ment or other primary malignancies, autoimmunity tests
(anti-nuclear, anti-cardiolipin and anti-thyroglobulin anti-
bodies) and haemolysis tests (reticulocytes, Coombs tests).
A CT scan and blood stool analysis are also necessary to
exclude disease progression. A severe acute reduction in
Hb, reduction in haematocrit and RBC levels with an
increase in reticulocytes, elevated indirect bilirubin and a
positive direct Coombs test are all suggestive of auto-
immune anaemia. Our suggested work-up for suspected
autoimmune anaemia and leukopenia is shown in Figure 1.
All three of these patients were hospitalised and studied
to exclude other causes for haematological changes. The
results of autoimmunity tests performed were positive andClinical presenta
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Figure 1 Work-up for suspected autoimmune anaemia and leukopen
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effects treatment algorithms specifically developed for the
management of immune-related adverse events associated
with ipilimumab [9]. High doses of intravenous methyl-
prednisolone at 1 to 2mg/kg twice a day (in case of grade
4 or severe toxicity) or 1mg/kg a day of oral prednisone
(in case of grade 3 toxicity) are the recommended cortico-
steroid choice with the support of antibiotics, GM-CSF
and blood transfusion. This approach has been shown to
be effective and safe.
A possible explanation for this autoimmune anaemia
is that ipilimumab increases the production of auto-
antibodies against RBCs, as has been observed in some
patients receiving another anti-CTLA-4, tremelimumab
[10]. In two previous cases in the literature that describe
anaemia [5] or neutropenia [6] associated with ipilimu-
mab treatment, both reported aplasia/hypoplasia of cells
in bone marrow biopsy with ipilimumab-related patho-
genesis thought to be due to lymphocyte infiltration.
Although we observed lymphocyte infiltration in two of
our patients (cases 2 and 3), no aplasia/hypoplasia was
detected. Moreover, unlike our patients, these previously
reported cases were not responsive to corticosteroids. In
our third case, the patient had no haemolysis and anaemia
was normochromic and normocytic with a negative Coombs
test. Thus, we suggest that ipilimumab-related haemato-
logical toxicity may be mediated by different autoim-
munity mechanisms that result in different toxicities (for
example the development of RBC auto-antibodies causing
anaemia with a positive Coombs test or ipilimumab-
stimulated lymphocyte infiltration of the bone marrow,
resulting in a lymphocyte ‘traffic jam’ block with subse-
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blockade typically occur during treatment within 12 weeks
of initial dosing [11]. The occurrences of haematological
toxicities in two of our patients were consistent with these
findings, with onset after the third ipilimumab dose. How-
ever, our third case indicates the possibility of a late or
delayed toxicity that can occur a considerable time after
cessation of treatment. This suggests there is a need to
continue complete blood count assessments during long-
term follow-up of ipilimumab-treated patients.
Early ipilimumab trials suggested an association between
development of immune-related adverse events and clinical
response [12]. Although no such correlation was seen in
the Italian EAP, with disease control rates of 35.3% in pa-
tients with and 33.9% in those without immune-related
side effects [13], all three patients with haematological tox-
icity described here had a response to ipilimumab.
Conclusions
In conclusion, these reports suggest that, although un-
common, haematological toxicity can occur both during
and after treatment with ipilimumab. If promptly recog-
nised and treated, this toxicity is manageable and can be
reversed with standard corticosteroid treatment as recom-
mended for other ipilimumab immune-related side effects.
As such, clinicians should be aware of the possibility
of these less frequent types of immune-related adverse
events with ipilimumab.
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